Kornimate/medical-research-clean huggingface dataset:
trimethylamine n-oxide (tmao) levels in periodontal disease

Conditions: Periodontitis; Smoking; Inflammatory Response

Summary: salivary and serum levels of tmao and tnf-a can distinguish between individuals with periodontitis and periodontally healthy persons, including smoking and nonsmoking patients.

tobacco use is a prevalent global habit with notable impacts on general health and periodontal disease. trimethylamine n-oxide (tmao) is a compound involved in the pathogenesis of various systemic inflammatory diseases, including cardiovascular conditions. the aim of this study was to determine differences in saliva and serum levels of tmao between periodontitis and periodontally healthy patients according to smoking status. the study includes four groups: systemically and periodontally healthy non-smokers (ns- control; n = 25), systemically healthy non-smokers with stage-iii grade-b periodontitis (ns- periodontitis; n = 25), systemically and periodontally healthy smokers (s-control; n = 25), and systemically healthy smokers with stage-iii grade-c periodontitis (s-periodontitis; n = 25). periodontal parameters were recorded. tmao levels were determined in saliva and serum samples using liquid chromatography-mass spectrometry (lc-ms/ms). tnf-α levels were measured by elisa method.

Eligibility criteria:
inclusion criteria: * • systemically healthy * clinical diagnosis of periodontitis * clinical diagnosis of periodontal health * for smoking group : denied as smoking at least 10 cigarettes per day and the duration should more than 10 years. exclusion criteria: * decline to participate and being under 18 \& over 65 years of age; (2) having any systemic inflammatory diseases such as diabetes, rheumatoid arthritis, or systemic conditions, including immunodeficiency syndrome, cardiovascular disorders, or hepatic disorders; (3) the use of antibiotics and/or anti-inflammatory nonsteroidal anti-inflammatory drugs within 3 months preceding the study; (4) having nonsurgical periodontal treatment (previous 6 months); (5)having surgical periodontal treatment (previous 12 months); (6)having \<20 natural teeth excluding the third molars.

Keywords: periodontal disease smoking tmao
comparison of carbon dioxide and saline flush to saline flush in tevar and tavi procedures to reduce cerebral ischemia

Conditions: Thoracic Aortic Aneurysm; Aortic Stenosis Symptomatic; Stroke, Complication

Summary: thoracic endovascular repair (tevar) and transcatheter aortic valve implantation (tavi) are standard of care procedures to treat thoracic aortic aneurysm or severe aortic stenosis, respectively. both procedures have a high risk of stroke and silent infarction. gas has been detected in the cerebral vasculature during these procedures and associated with dwi positive lesions on mri. the hypothesis is that air emboli contribute to stroke and silent infarction. the investigators propose addressing air emboli by flushing the device with carbon dioxide prior to flushing with saline. this is a pilot study comparing standard saline flush alone to carbon dioxide flushing with saline flush.


Eligibility criteria:
inclusion criteria: * elective tevar or tavi * over 18 years old exclusion criteria: * recent acute myocardial infarction * recent stroke or tia * post or pending organ transplantation * active peptic ulcer disease * recent gastrointestinal bleed * history of bleeding diathesis or coagulopathy or contraindications to antiplatelet or anticoagulant therapy. * permanent pacemaker or icd * history of atrial fibrillation * moderate or severe allergy to iodinated contrast not amenable to predmedication * renal failure * unable to safely undergo mri * enrollment in another study
gastrointestinal study at orkambi therapy in cf patients

Conditions: Cystic Fibrosis

Summary: ivacaftor caused a significance increase in weight in patients carrying the g551d mutation and the etiology of this has largely remained unknown but may be due to improved function of the gastrointestinal tract. the combination therapy of orkambi has been recently approved for subjects with cystic fibrosis homozygous for f508del mutation. this provides an opportunity to examine if there are any improvements in gastrointestinal function. the investigators aim to investigate various aspects of gastrointestinal and pancreatic function before and 6 months after the commencement of orkambi therapy.

to examine the entire intestinal mucosa via capsule endoscopy before and 6 months after orkambi therapy to ascertain if the inflammatory changes in the intestine have improved. a marker of intestinal inflammation measured in the stool, calprotectin, will be examined before and 6 months after orkambi treatment. the investigators hypothesize that the result will be reduced on therapy. a marker of pancreatic exocrine function, pancreatic elastase, will be examined before and 6 months after therapy to examine if the result has increased indicating improvement of exocrine pancreatic function study population all subjects with cf homozygous for the f508del mutation in sweden eligible for orkambi therapy, i.e. above 12 years of age, in total 145 patients in sweden of which 60 are taken care of at stockholm cf center; the investigators aim to examine 20 patients. study duration the duration will be 6 months for each patient.

Eligibility criteria:
inclusion criteria: * cf patients f508del homozygote * \>12 years of age * eligible for orkambi therapy. exclusion criteria: * patients who the patency capsule does not pass within 48 hrs * fev1\<30% * pregnancy and breastfeeding women * liver function blood tests (ast, alt, gamma-gt, alp) \>3 xuln * bilirubin \>2 xuln * ast or alt alone \>5 xuln * previous lung transplant
rjbc-app and breast cancer treatment compliance

Conditions: Breast Cancer

Summary: the goal of this multicentric randomized controlled clinical trial is to test the role of mobile medical application (app) on adjuvant therapy compliance and quality of life (qol) in patients with early breast cancer. participants assigned to the ruijin breast cancer app (rjbc-app) group can receive treatment reminders, matters needing attention as well as science knowledge and they can communicate with the medical staff during adjuvant treatments while follow-up can only be conducted in outpatient clinic for those in the control group.

adjuvant treatments has significantly improved the prognosis of early breast cancer patients. however, previous studies suggested the existence of noncompliance to adjuvant therapies, which might cause detriments to disease outcomes. the goal of this multicentric randomized controlled clinical trial is to test the role of mobile medical application (app) on adjuvant therapy compliance and quality of life (qol) in patients with early breast cancer. patients diagnosed with invasive breast cancers after surgery will be randomly assigned to the ruijin breast cancer app (rjbc-app) group or the control group. those in the rjbc-app group can receive treatment reminders, matters needing attention as well as science knowledge and they can communicate with the medical staff during adjuvant treatments while follow-up can only be conducted in outpatient clinic for those in the control group. the primary endpoint is the rate of adjuvant therapy compliance at 12 months after randomization. secondary endpoints consist of compliance rates at 3, 6, 24 months after randomization, qol and cancer-related symptoms scores at 3, 6, 12, 24 months, disease-free survival (dfs) and overall survival (os) at 60 months.

Eligibility criteria:
inclusion criteria: 1. females aged 18-70 2. eastern cooperative oncology group performance status score 0-2 3. breast cancer by pathology 4. adjuvant therapy by multidisciplinary team 5. written informed consent form exclusion criteria: 1. distant metastases at diagnosis 2. unable to use a smartphone
efficacy and durability of hepatitis a vaccination in patients with advanced fibrosis and cirrhosis

Conditions: Cirrhosis; Hep A; Vaccination

Summary: the hepatitis a virus (hav) is a significant global public health concern. the hepatitis a virus is transmitted primarily by the faecal-oral route, leading to acute hepatitis. symptoms include low-grade fever, anorexia, jaundice, and typically resolve without complications. however, hav infection in patients with chronic liver disease, especially those over 50 years old, may result in more severe outcomes, including fulminant hepatitis, with a higher mortality rate compared to the general population hav vaccination is a cornerstone of prevention, especially in high-risk groups. currently, there is a recommendation to vaccinate patients with chronic liver disease against hav infection. however, these patients often have compromised immune responses, leading to lower vaccine efficacy compared to the general population. the goal of this randomized controlled trial is to compare the efficacy and safety of the standard 2-dose (0, 6 months) hepatitis a vaccination regimen with an intensive 3-dose (0, 1, 6 months) schedule in patients with advanced fibrosis and cirrhosis. the main questions it aims to answer are: * compared the seroconversion rate of the standard 2-dose (0, 6 months) hepatitis a vaccination regimen versus the intensive 3-dose (0, 1, 6 months) hepatitis a vaccination regimen in patients with advanced fibrosis and cirrhosis. * compared the antibody levels against the hepatitis a virus (anti-hav igg) of the standard 2-dose (0, 6 months) hepatitis a vaccination regimen versus the intensive 3-dose (0, 1, 6 months) hepatitis a vaccination regimen in patients with advanced fibrosis and cirrhosis.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * confirmed advance fibrosis (f3) or cirrhotic (f4) status (radiologic finding or liver stiffness measurement or pathological report) * negative anti-hav igm, igg at baseline exclusion criteria: * positive anti-hav igg at baseline * autoimmune hepatitis * current hepatocellular carcinoma * active other malignancies * presence of antibodies against human immunodeficiency virus * received immunosuppressive drugs * pregnancy or lactation * decompensated cirrhosis with meld ≥ 15 * chronic illness or bedridden patient who cannot travel to hospital * lack of consent to participate in the study

Keywords: cirrhosis hav hepatitis a hav vaccine
human umbilical cord blood infusion in patients with cerebral palsy

Conditions: Cerebral Palsy

Summary: a phase i, randomized, double-blind, placebo-controlled clinical study to assess the safety and efficacy of allogeneic human umbilical cord blood infusion in children with cerebral palsy

this is a phase i study to evaluate the safety and efficacy in hucb treatment on the patients with cerebral palsy (cp).

Eligibility criteria:
inclusion criteria: * male or female underage at the time of screening. * with a confirmed diagnosis of cp * non-progressive motor disability * brain dysfunction exclusion criteria: * judged by the investigator to be not suitable/eligible for study participation.
local therapy for oligometastatic escc patients treated with pd-1 inhibitor

Conditions: Esophageal Squamous Cell Carcinoma; Oligometastatic Disease; Radiotherapy

Summary: patients with oligometastatic squamous cell carcinoma were enrolled and randomly assigned to receive either pd-1 inhibitor +/- chemotherapy combined with local therapy or pd-1 inhibitor +/- chemotherapy alone. the primary end point was progression-free survival (pfs). the secondary end points included overall survival, side effects and local control.

patients with oligometastatic squamous cell carcinoma were enrolled and 2:1 randomly assigned to receive either pd-1 inhibitor +/- chemotherapy combined with local therapy (radiotherapy, surgery, radiofrequency/microwave ablation, etc.) or pd-1 inhibitor +/- chemotherapy alone. different local therapy techniques are allowed to be used on different lesions in the same patient.all suspected malignant lesion should be included in local treatment planning in principle. the primary end point was progression-free survival (pfs). the second end points included overall survival, side effects and local control.

Eligibility criteria:
inclusion criteria: * 1. ≥18 years old; 2. ecog 0-1; 3. esophageal squamous cell carcinoma 4. astro/estro defined genuine oligometastatic disease and consistent with: i. ≤4 distant metastases, ii. ≤3 metastatic lesions within a single organ, iii. maximum diameter of each metastatic lesion ≤5cm; 5. ≥1 pathologically diagnosed metastases exclusion criteria: * 1. history of disseminated metastases or astro/estro defined induced oligometastatic disease 2.esophageal perforation/hemorrhage 3.progression disease after pd-1 inhibitor treatment 4.in-field recurrence 5.intolerance to chemotherapy or immunotherapy 6.lung v20\>25%

Keywords: esophageal squamous cell carcinom oligometastatic radiotherapy pd-1 inhibitor
a study to assess the pk and safety of pt010 in subjects with copd following single and repeat dose

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this is a phase i open-label, single center study to assess the pk and safety of bgf mdi 320/14.4/9.6 µg in subjects with moderate to severe copd. pharmacokinetics will be assessed following a single dose administration on the first treatment day (day 1) and will be assessed again after 7 days of repeat dosing. this study includes a screening period of up to 28 days and a single treatment period of 8 days. a follow-up phone call will be conducted at least 5 days but no longer than 7 days after the last dose of study drug.


Eligibility criteria:
key inclusion criteria: * given their signed written informed consent to participate. * non-child bearing potential (ie, physiologically incapable of becoming pregnant, including any female who is 2 years post-menopausal); or child bearing potential, has a negative serum pregnancy test at visit 1, and agrees to acceptable contraceptive methods used consistently and correctly for the duration of the study. * subjects with an established clinical history of copd as defined by the american thoracic society (ats)/european respiratory society (ers), or other local applicable guidelines. * current or former smokers with a history of at least 10 pack-years of cigarette smoking. * pre-bronchodilator fev1/fvc ratio must be \<0.70 and pre-bronchodilator fev1 must be ≥50% and \<80% predicted normal value calculated using national health and nutrition examination survey (nhanes) iii reference equations key exclusion criteria: * significant diseases or conditions to : other than copd, active pulmonary disease such as active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, primary pulmonary hypertension, interstitial lung disease and uncontrolled sleep apnea . * women who are pregnant or lactating, or are planning to become pregnant during the course of the study, or women of childbearing potential who are not using an acceptable method of contraception. * subjects, who in the opinion of the investigator, have a current diagnosis of asthma. * subjects who have a history of hypersensitivity to any corticosteroid, * β2-agonist, muscarinic anticholinergic, or any component of the mdi * alpha-1 antitrypsin deficiency as the cause of copd
quadratus lumborum block for pediatric hip surgery

Conditions: Hip Dislocation, Congenital; Postoperative Pain; Anesthesia

Summary: caudal blockade (cb) is one of the most frequently performed regional anaesthetic techniques in children. it's an efficient way to offer perioperative analgesia for painful sub-umbilical interventions but with high incidence of motor block and urinary retention. in one study, psoas compartment block was associated with less morphine comsumption and prolonged duration of analgesia compared to single-shot caudal block in small children undergoing open hip reduction/osteotomies. ultasound guided anterior quadratus lumborum block (aqlb) provides unilateral analgesia to the nerves between the psoas muscle (pm) and the quadratus lumborum muscle (qlm). the first pediatric study evaluating quadratus lumborum block is encouraging . the first pediatric study evaluating quadratus lumborum block is encouraging. to the best of the investigator's knowledge, there are no previously published data comparing the aqlb with other regional techniques in infants undergoing hip surgery.

the aim of this prospective randomized study was to compare the analgesic effects between aqlb and cb in children undergoing unilateral open hip reduction/osteotomies for hip dislocation. patients were randomly assigned, into 1 of 2 groups, namely, group cb (n = 20) and group aqlb (n = 20). preoperatively all children were premedicated by using oral midazolam (0 .5mg/kg). anesthesia was induced with 3 to 4% sevoflurane and 50% with 60% nitrous oxide in oxygen.then fentanyl 3 μg/kg and propofol 1 - 2mg/kg were administered for anesthesia induction. airway was secured with endotracheal tube placed in the mouth facilited by 0.15 mg/kg cistracurium. anesthesia maintenance was performed with sevoflurane 2% in 50% nitrous oxide. aqlb and cb were done with 1 ml/kg, 0.25% ropivacaine (maximum dose limited to 20 ml) postoperative follow-up: all patients received 15 mg/kg paracetamol before extubation. tramadol 2 mg/kg intravenous was planned as rescue analgesia when cheops score was more than 3. supplemental iv tramado, 1 mg/kg could be added if necessary every 6 hours.

Eligibility criteria:
inclusion criteria: * patients aged 2 to 7 years old * weight ≤ 20 kg * american society of anesthesiologists (asa) physical status i or ii * planned to undergo unilateral open hip reduction/osteotomies exclusion criteria: * cerebral palsy with severe intellectual disability * coagulation disorders * local or general infection * allergy to amide local anesthetics. * progressive neurological disorders * parenteral refusal * spinal dysraphism * cutaneous anomalies (angioma, hair truft, naevus or a dimple)near to the puncture

Keywords: hip dislocation regional anesthesia surgery
a study on pain after breast reconstruction

Conditions: Mastectomy; Mastectomy Patient; Mastectomy and Breast Reconstruction; Breast Reconstruction; Breast Reconstruction After Mastectomy; Postmastectomy Pain

Summary: the purpose of this study is to find out how common persistent postmastectomy pain (ppmp) is among people who have had a mastectomy and breast reconstruction surgery for their breast cancer. the study will also look at how effective regenerative peripheral nerve interface (rpni) surgery is for reducing pain from neuropathic ppmp after breast reconstruction.


Eligibility criteria:
inclusion criteria: * female * age ≥18 years * history of mastectomy for breast cancer or genetic predisposition to breast cancer * history of breast reconstruction with implants and/or autologous tissue * at least 6 months of follow-up after reconstruction * patient treated at msk exclusion criteria: * exchange or revision surgery within 6 months * active medical reason for pain (e.g., infectious, neoplastic, wound related) * greater than 15 years post-reconstruction

Keywords: postmastectomy pain breast reconstruction after mastectomy breast reconstruction mastectomy and breast reconstruction mastectomy mastectomy patient 24-271 memorial sloan kettering cancer center
prospective evaluation of targeted axillary dissection (tad)

Conditions: Breast Cancer

Summary: the purpose of this research is to evaluate how to manage the axillary lymph nodes in patients with breast cancer. the investigators will determine if a sampling of the lymph nodes under the arm will give the information necessary to determine if fewer lymph nodes can be removed.


Eligibility criteria:
inclusion criteria: * women or men greater than or equal to 18 years. * histologically confirmed invasive adenocarcinoma of the breast. * clinical t0-4 n2-3 m0 at diagnosis (american joint committee on cancer, 7th edition) * assessment for cn2 disease will be performed by clinical exam and imaging. patients should have pathologic level 1 and/or 2 axillary lymph nodes which are fixed/matted on physical exam. * cross-sectional imaging will be used to identify advanced nodal disease involving the axilla, infraclavicular, supraclavicular, and internal mammary regions, cn3 disease. * patients must have biopsy proven involvement of the axillary lymph nodes. * receipt of standard multiagent chemotherapy +/- targeted therapy based on tumor subtype. * candidate for surgical management of breast cancer. * ability to understand and willingness to sign a written informed consent document. exclusion criteria: * history of allergic reactions or hypersensitivity to radioactive lymph node mapping agents or blue dye. * pregnancy.

Keywords: targeted axillary dissection advanced nodal disease axillary lymph node
physical fitness impact of early physiotherapy intervention with a standardized exercise therapy program in adult patients receiving intensive induction chemotherapy for treatment of acute leukemia during extended hospitalization.

Conditions: Acute Leukemia

Summary: this study aimed to investigate the impact of physical therapy in adult patients receiving intensive induction chemotherapy for the treatment of acute leukemia during prolonged hospitalization. the study cohort included 150 patients. primary objective is to compare the effect of a standardized rehabilitation program on physical deconditioning. this study has several secondary objectives of comparing and analyzing the status of sarcopenia, muscle strength, physical performance and the psychic dimension of this intervention. the 6 minutes walking test, handgrip strength, impedance measurement, computed tomography, short physical performance were used as measures of physical function. hospital anxiety and depression scale and european organization for the research and treatment of cancer-quality of life-questionnaire-30 (eortc-qlq-30) were used as measures of depression and anxiety and quality of life of cancer patients. to investigate the impact of physical therapy, patients were assigned to the physical therapy group (experimental group) or the control group.these results will thus make it possible to promote access to physiotherapy and rehabilitation care, from diagnosis and during hospitalization, and to standardize practices.


Eligibility criteria:
inclusion criteria: * adult patient \>18 years * patient with acute leukemia eligible to receive intensive chemotherapy (induction phase) with predictable deep bone marrow aplasia (polynuclear neutrophils \<500mm3 for more than 8 days) requiring prolonged hospitalization with room confinement. * patient having signed the informed consent to participate in the study exclusion criteria: * patient with disabilities or contraindications (significant cognitive or psychiatric disorders, significant cardiac or pulmonary pathology, neurological, joint, orthopedic or medical condition, etc.) following an exercise therapy program and carrying out follow-up defined by the protocol and in particular the physical performance tests. * active bleeding, acute thrombosis, ischemia, hemodynamic instability or uncontrolled pain * no understanding of the french language * pregnant women, parturients and nursing mothers * persons deprived of their liberty by judicial or administrative decision * people under duress psychiatric care * persons subject to legal protection * persons unable to express their consent * person not affiliated to a health insurance scheme or not beneficiary of a social security scheme.

Keywords: sarcopenia exercise cancer related fatigue